ANCHOR STUDY GROUP. RANIBIZUMAB VERSUS VERTEPORFIN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

By David M. Brown, P. Kaiser, M. Michels, G. Soubrane, J. Heier, R. Kim. 2006

690 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. (2014, unknown): “Neovascularization in AMD (ANCHOR) and the Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular AMD (MARINA), showed clear superiority of monthly intravitreal ranibizumab administration compared with sham or with the previous gold standard, photodynami”
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration: 2-Year Results (2012, background): “t r a i c Clinical trials established ranibizumab as a highly effective treatment for neovascular age-related macular degeneration (AMD), the leading cause of legal blindness in the United States.(1,2) While awaiting approval of ranibizumab by the Food and Drug Administration, ophthalmologists began”
Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. (2009, methodology): “At 12 months (the prespecified primary efficacy analysis), ranibizumab had superior efficacy to PDT as indicated by both visual acuity (VA) measures and changes in CNV lesion characteristics.(6) The percentage of patients who had lost fewer than 15 letters from baseline VA (primary efficacy end poin”